Outcomea | n | Balanced (n = 131) | Saline (n = 130) | P Value |
---|---|---|---|---|
Primary Outcomes | ||||
 Day 2 urinary NGAL level – ng/mg (IQR) | 261 | 39.4 [9.9–133.2] | 64.4 [27.6–339.9] | < 0.001 |
 Day 2 urinary KIM-1 level – ng/mg (IQR) | 261 | 2.7 [1.5–4.9] | 2.4 [1.3–5.0] | 0.36 |
Secondary Biomarker Outcomes | ||||
 Change in NGAL level from day 0 to 2 | 111 | −27.7 [− 293.4–2.3] | −7.8 [− 115.9–25.7] | 0.14 |
 Change in KIM-1 level from day 0 to 2 | 111 | −0.59 [− 2.9–1.21] | −0.29 [− 1.48–0.48] | 0.79 |
Secondary Clinical Outcomes | ||||
 30-day in-hospital mortality – no. (%) | 261 | 5 (4%) | 10 (8%) | – |
 Major Adverse Kidney Event within 30 days – no. (%)b | 261 | 13 (10%) | 17 (13%) | – |
 Intensive care unit-free daysc | 260 | 25.0 [23.0–26.0] | 25.0 [23.0–25.0] | – |
  Mean ± SD |  | 22.5 ± 6.5 | 21.8 ± 7.2 |  |
 Ventilator-free daysc | 260 | 28.0 [28.0–28.0] | 28.0 [27.0–28.0] | – |
  Mean ± SD |  | 25.8 ± 6.3 | 25.1 ± 7.6 |  |
 Vasopressor-free daysc | 260 | 28.0 [27.0–28.0] | 28.0 [28.0–28.0] | – |
  Mean ± SD |  | 26.0 ± 6.2 | 25.6 ± 7.1 |  |
 Renal replacement therapy-free daysc | 260 | 28.0 [28.0–28.0] | 28.0 [28.0–28.0] | – |
  Mean ± SD |  | 26.6 ± 5.8 | 25.3 ± 7.9 |  |
 Stage II or greater AKI developing after enrollment – no. (%)d | 261 | 50 (39%) | 48 (37%) | – |
 New receipt of RRT | 261 | 1 (1%) | 3 (2%) | – |
 Creatinine, mg/dL | ||||
  Highest before discharge or day 30 | 260 | 1.32 [0.95–1.96] | 1.17 [0.81–1.85] | – |
  Final value before discharge or 30 days | 259 | 0.84 [0.72–1.15] | 0.79 [0.68–1.07] | – |